[{"address1": "321 Summer Street", "address2": "Suite 400", "city": "Boston", "state": "MA", "zip": "02210", "country": "United States", "phone": "857 330 4340", "website": "https://www.inozyme.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases in the United States. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein, which is in Phase 1/2 clinical trials for the treatment of ENPP1 and ABCC6 deficiency, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 56, "companyOfficers": [{"maxAge": 1, "name": "Dr. Douglas A. Treco Ph.D.", "age": 65, "title": "CEO & Chairman", "yearBorn": 1958, "fiscalYear": 2022, "totalPay": 77000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Axel  Bolte M.B.A., M.Sc.", "age": 51, "title": "Co-Founder, Senior Advisor & Director", "yearBorn": 1972, "fiscalYear": 2022, "totalPay": 1034857, "exercisedValue": 0, "unexercisedValue": 11006}, {"maxAge": 1, "name": "Mr. Sanjay S. Subramanian M.B.A., M.S.", "age": 46, "title": "Senior VP, CFO & Principal Accounting Officer", "yearBorn": 1977, "fiscalYear": 2022, "totalPay": 726300, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Demetrios  Braddock M.D., Ph.D.", "title": "Co-Founder, Scientific Founder, Member of Scientific Advisory Board & Board Observer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Matthew  Winton Ph.D.", "age": 45, "title": "Senior VP & COO", "yearBorn": 1978, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Soojin  Kim Ph.D.", "title": "Senior VP & Chief Technical Operations Officer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David  Thompson M.A., M.S., Ph.D.", "title": "Senior VP, Chief Scientific Officer & Chief Development Officer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stefan  Riley", "title": "Director of Investor Relations", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Gayle  Gironda", "title": "Senior VP & Chief People Officer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Yves  Sabbagh Ph.D.", "title": "Chairman of Scientific Advisory Board & Senior VP", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 2, "previousClose": 4.71, "open": 4.72, "dayLow": 4.72, "dayHigh": 5.47, "regularMarketPreviousClose": 4.71, "regularMarketOpen": 4.72, "regularMarketDayLow": 4.72, "regularMarketDayHigh": 5.47, "beta": 1.288, "forwardPE": -4.067164, "volume": 692039, "regularMarketVolume": 692039, "averageVolume": 399346, "averageVolume10days": 319010, "averageDailyVolume10Day": 319010, "bidSize": 900, "askSize": 1100, "marketCap": 336595808, "fiftyTwoWeekLow": 1.96, "fiftyTwoWeekHigh": 7.33, "fiftyDayAverage": 4.0683, "twoHundredDayAverage": 4.7877, "currency": "USD", "enterpriseValue": 178254080, "floatShares": 34269804, "sharesOutstanding": 61760700, "sharesShort": 2742730, "sharesShortPriorMonth": 1598899, "sharesShortPreviousMonthDate": 1702598400, "dateShortInterest": 1705017600, "sharesPercentSharesOut": 0.0444, "heldPercentInsiders": 0.0065200003, "heldPercentInstitutions": 0.87802005, "shortRatio": 5.14, "shortPercentOfFloat": 0.044699997, "impliedSharesOutstanding": 61760700, "bookValue": 2.594, "priceToBook": 2.1010022, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -68169000, "trailingEps": -1.44, "forwardEps": -1.34, "pegRatio": -0.26, "enterpriseToEbitda": -2.491, "52WeekChange": 0.94628096, "SandP52WeekChange": 0.20883334, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "INZY", "underlyingSymbol": "INZY", "shortName": "Inozyme Pharma, Inc.", "longName": "Inozyme Pharma, Inc.", "firstTradeDateEpochUtc": 1595597400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "f627b06e-ce15-3126-896c-1db8a4222086", "messageBoardId": "finmb_568596329", "gmtOffSetMilliseconds": -18000000, "currentPrice": 5.45, "targetHighPrice": 40.0, "targetLowPrice": 16.0, "targetMeanPrice": 22.0, "targetMedianPrice": 16.0, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 4, "totalCash": 192442000, "totalCashPerShare": 3.116, "ebitda": -71548000, "totalDebt": 34100000, "quickRatio": 15.678, "currentRatio": 16.363, "debtToEquity": 21.284, "returnOnAssets": -0.25148, "returnOnEquity": -0.46217, "freeCashflow": -43788248, "operatingCashflow": -66588000, "financialCurrency": "USD", "trailingPegRatio": null}]